Year |
Citation |
Score |
2021 |
Puvvula PK, Yu Y, Sullivan KR, Eyob H, Rosenberg J, Welm A, Huff C, Moon AM. Inhibiting an RBM39/MLL1 epigenomic regulatory complex with dominant-negative peptides disrupts cancer cell transcription and proliferation. Cell Reports. 35: 109156. PMID 34077726 DOI: 10.1016/j.celrep.2021.109156 |
0.621 |
|
2016 |
Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine. PMID 27775705 DOI: 10.1038/Nm.4213 |
0.637 |
|
2016 |
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nature Medicine. PMID 26950360 DOI: 10.1038/Nm.4055 |
0.607 |
|
2016 |
Horiuchi D, Zhou AY, Corella AN, Yau C, Balakrishnan S, Kessenbrock K, Lawson DA, Camarda R, Anderton BN, Bazarov AV, Eyob H, Rohrberg J, Yaswen P, McManus MT, Rugo HS, et al. Abstract B34: PIM kinase as a novel therapeutic target for triple-negative breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B34 |
0.677 |
|
2016 |
Goga A, Camarda R, Zhou A, Kohnz R, Balakrishnan S, Anderton B, Mahieu C, Eyob H, Krings G, Nomura D. Abstract PD3-05: Inhibition of fatty-acid oxidation as a therapy for triple-negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd3-05 |
0.574 |
|
2016 |
Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, Nomura DK, Goga A. Abstract 2673: Inhibition of fatty-acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer Cancer Research. 76: 2673-2673. DOI: 10.1158/1538-7445.Am2016-2673 |
0.596 |
|
2015 |
Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, Yaswen P, Goga A, Werb Z. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. PMID 26416748 DOI: 10.1038/Nature15260 |
0.522 |
|
2015 |
Camarda R, Balakrishnan S, Zhou AY, Anderton B, Eyob H, Kohnz R, Nomura DK, Goga A. Abstract A03: Integrative analyses reveal distinct metabolic dysregulation in MYC-driven, basal breast cancer Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-A03 |
0.591 |
|
2013 |
Eyob H, Ekiz HA, Welm AL. RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. Oncoimmunology. 2: e25670. PMID 24327933 DOI: 10.4161/Onci.25670 |
0.651 |
|
2013 |
Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discovery. 3: 751-60. PMID 23612011 DOI: 10.1158/2159-8290.Cd-12-0480 |
0.609 |
|
2011 |
Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL. Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes & Cancer. 2: 753-62. PMID 22207901 DOI: 10.1177/1947601911421924 |
0.675 |
|
2010 |
Kretschmann KL, Eyob H, Buys SS, Welm AL. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Current Drug Targets. 11: 1157-68. PMID 20545605 DOI: 10.2174/138945010792006825 |
0.677 |
|
Show low-probability matches. |